QI
ANIK icon

Quotient Investors’s Anika Therapeutics ANIK Stock Holding History

Quotient Investors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,543
Closed -$208K – 218
2015
Q3 		$208K Sell
6,543
-10,057
-61% -$351K 0.05% 193
2015
Q2 		$548K Hold
16,600
– – 0.07% 162
2015
Q1 		$683K Buy
16,600
+11,400
+219% +$461K 0.09% 146
2014
Q4 		$212K Buy
+5,200
New +$203K 0.04% 226
2014
Q3 		– Sell
-5,200
Closed -$241K – 241
2014
Q2 		$241K Hold
5,200
– – 0.05% 224
2014
Q1 		$214K Sell
5,200
-2,700
-34% -$100K 0.05% 213
2013
Q4 		$301K Sell
7,900
-2,200
-22% -$67.9K 0.07% 208
2013
Q3 		$242K Hold
10,100
– – 0.06% 222
2013
Q2 		$172K Buy
+10,100
New +$146K 0.05% 224

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Quotient Investors's ANIK Position: Q4 2015 in Review

Quotient Investors sold out of Anika Therapeutics (ANIK) in Q4 2015, closing a stake of 6,543 shares — an estimated $208K sold.

Quotient Investors first reported a position in ANIK in Q2 2013 and held it in 9 quarters. The position peaked at $683K in Q1 2015. 152 funds tracked by Wall St. Rank hold ANIK as of Q4 2015.

  • Quotient Investors reported no remaining Anika Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Quotient Investors sold 6,543 Anika Therapeutics shares in Q4 2015, an estimated $208K.
  • Quotient Investors first reported a position in Anika Therapeutics in Q2 2013 and held it in 9 quarters.
  • Quotient Investors's Anika Therapeutics position peaked at $683K in Q1 2015.
  • 152 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2015.

Based on Quotient Investors's 13F filing for Q4 2015, filed 14 Jan 2016.